Month: September 2017

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017

CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2017.  Recent and Fiscal Year Significant Highlights Bremelanotide …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 Read More »

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017

CRANBURY, N.J., Sept. 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter and fiscal year end 2017 operating results on Monday, September 25, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team …

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017 Read More »

Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors

Sep 12, 2017, 07:30 ET CRANBURY, N.J., Sept. 12, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to Palatin’s Board of Directors on September 7, …

Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors Read More »

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories

CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for exclusive rights to develop and commercialize bremelanotide for female sexual …

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories Read More »

Scroll to Top